  |
 | Up a level |
Paz-Ares, L. and Chen, Y. and Reinmuth, N. and Hotta, K. and Trukhin, D. and Statsenko, G. and Hochmair, M. J. and Özgüroglu, M. and Ji, J.H. and Garassino, M. C. and Voitko, O. and Poltoratskiy, A. and Musso, E. and Havel, L. and Bondarenko, I. and Losonczy, G. and Conev, N. and Mann, H. and Dalvi, T. B. and Jiang, H. and Goldman, J. W. (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, Vol. 7 (no. 2). p. 100408. ISSN 2059-7029 (Online)
Spigel, D.R. and Bondarenko, I. and Losonczy, G. and Mezger, J. and Kalofonos, H. and Reck, M. and Palmero, R. and Jang, T. and Natale, R. and Sanborn, R.E. and Lai, J. and Kallinteris, N. and Tang, M. and Shan, J. and Gerber, D. (2016) Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer. Annals of Oncology, Vol.27 (supp_6). P.- LBA45. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
